EGFR-TKI and lung adenocarcinoma with CNS relapse: Interest of molecular follow-up

European Respiratory Journal

Volumn 33, Issue 2, 2009, Pages 436-440

  Ruppert, A M ^a   Beau Faller, M ^a   Neuville, A ^a   Guerin, E ^a   Voegeli, A C ^a   Mennecier, B ^a   Legrain, M ^a   Molard, A ^a   Jeung, M Y ^a   Gaub, M P ^a   Oudet, P ^a   Quoix, E ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Brain metastases; Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitor; Lung cancer; Mutation

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CARCINOMATOUS MENINGITIS; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHROMATOGRAPHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DISEASE COURSE; DRUG WITHDRAWAL; EXON; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; LUNG ADENOCARCINOMA; MALE; METASTASIS; MOLECULAR EVOLUTION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; TREATMENT OUTCOME;

EID: 59649105302     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162307     Document Type: Article

References (16)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
4. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
5. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in nonsmall-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-8092.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
7. Paz-Ares L, Sanchez LM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine linase domain of the epidermal growth factor receptor. ASCO Meeting Abstracts 2006; 24: 7020.
8. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
9. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
10. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
11. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
12. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003; 123: 1868-1877.
13. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005; 103: 2344-2348.
14. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-6501.
15. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24: 4517-4520.
16. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13: 1511-1515.